Advertisement

Molecular and Cellular Biochemistry

, Volume 322, Issue 1–2, pp 127–135 | Cite as

Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis

  • A. Lubbad
  • M. A. Oriowo
  • I. Khan
Article

Abstract

Curcumin, an active ingredient of Curcumin longa mediates its anti-inflammatory effects through inhibition of NFkB. Several pathways including toll-like receptors (TLR) induce NFkB leading to inflammation. In this study, we investigated the effects of curcumin on the expression of TLR-4 and MyD88, the upstream signaling pathway in experimental colitis induced in the Sprague-Dawley male rats by intra-rectal administration of trinitrobenzenesulfonic acid (TNBS). The animals which received TNBS were divided into two groups: Group 1, received aqueous suspension of curcumin (100 mg/Kg body weight) 2 h prior to inducing colitis, and the treatment was repeated every day for 5 days, and Group 2 and non-colitis (Group 3) animals received phosphate buffered saline (PBS) in a similar fashion. Non-colitis animals (Group 4) received curcumin and served as controls. Animals were sacrificed on day 5 post-TNBS by cervical dislocation, colon was taken out, and cleaned with PBS. Levels of TLR-4, MyD88, and NFkB proteins were measured using ECL Western blot analysis, and TLR-4 mRNA by a competitive RT-PCR method. Colitis was confirmed histologically by measuring myeloperoxidase (MPO) activity and malondialdehyde (MDA) levels in the colonic tissues. TNBS-induced increase in the level of MPO activity and MDA concentrations was reversed by curcumin treatment, whereas the same dose of curcumin did not affect their levels in the non-colitis animals. Increases in the levels of TLR-4, MyD88, and NFkB proteins in inflamed tissue were also suppressed significantly by curcumin treatment. The level of TLR-4 mRNA remained unchanged in the colitis animals. These findings demonstrate that signaling pathway of curcumin-induced inhibition of inflammation involves TLR-4 and MyD88, and therefore may serve as an important therapeutic target in IBD.

Keywords

Inflammatory bowel disease Toll-like receptor MPO MDA MyD88 NFkB Colitis 

Notes

Acknowledgments

Financial support from the Kuwait University Research Administration through a graduate student research grant # MY06/06, and Miss Amna Al-Shamali for technical assistance.

References

  1. 1.
    Schmidt C, Stallmach A (2005) Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol Dietol 51(2):127–145PubMedGoogle Scholar
  2. 2.
    Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182–205PubMedCrossRefGoogle Scholar
  3. 3.
    Atreya I, Atreya R, Neurath MF (2008) NF-kappaB in inflammatory bowel disease. J Intern Med 263(6):591–596. doi: 10.1111/j.1365-2796.2008.01953.x (Review)PubMedCrossRefGoogle Scholar
  4. 4.
    Kaser A, Tilg H (2008) Novel therapeutic targets in the treatment of IBD. Expert Opin Ther Targets 12(5):553–563. doi: 10.1517/14728222.12.5.553 PubMedCrossRefGoogle Scholar
  5. 5.
    Hanauer SB (1996) Inflammatory bowel disease. N Engl J Med 334(13):841–848. doi: 10.1056/NEJM199603283341307 (Review)PubMedCrossRefGoogle Scholar
  6. 6.
    Pari L, Tewas D, Eckel J (2008) Role of curcumin in health and disease. Arch Physiol Biochem 114(2):127–149. doi: 10.1080/13813450802033958 (Review)PubMedCrossRefGoogle Scholar
  7. 7.
    Kozuch PL, Hanauer SB (2008) Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 14(3):354–377. doi: 10.3748/wjg.14.354 (Review)PubMedCrossRefGoogle Scholar
  8. 8.
    Billerey-Larmonier C, Uno JK, Larmonier N, Midura AJ, Timmermann B, Ghishan FK, Kiela PR (2008) Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent. Inflamm Bowel Dis 14(6):780–793. doi: 10.1002/ibd.20348 PubMedCrossRefGoogle Scholar
  9. 9.
    Holt PR, Katz S, Kirshoff R (2005) Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 50(11):2191–2193. doi: 10.1007/s10620-005-3032-8 PubMedCrossRefGoogle Scholar
  10. 10.
    Boone DL, Ma A (2003) Connecting the dots from toll-like receptors to innate immune cells and inflammatory bowel disease. J Clin Invest 111(9):1284–1286PubMedGoogle Scholar
  11. 11.
    Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216. doi: 10.1146/annurev.immunol.20.083001.084359 PubMedCrossRefGoogle Scholar
  12. 12.
    Bou-Fersen AM, Anim JT, Khan I (2008) Experimental colitis is associated with ultrastructural changes in inflamed and uninflamed regions of the gastrointestinal tract. Med Princ Pract 17(3):190–196. doi: 10.1159/000117791 PubMedCrossRefGoogle Scholar
  13. 13.
    Al-Jarallah A, Khan I, Oriowo MA (2008) Role of Ca2+-sensitization in attenuated carbachol-induced contraction of the colon in a rat model of colitis. Eur J Pharmacol 579(1–3):365–373. doi: 10.1016/j.ejphar.2007.10.069 PubMedCrossRefGoogle Scholar
  14. 14.
    Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL (1989) Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96(3):795–803PubMedGoogle Scholar
  15. 15.
    Khan I, Oriowo MA, Anim JT (2005) Amelioration of experimental colitis by Na–H exchanger-1 inhibitor amiloride is associated with reversal of IL-1ss and ERK mitogen-activated protein kinase. Scand J Gastroenterol 40(5):578–585. doi: 10.1080/00365520510012352 PubMedCrossRefGoogle Scholar
  16. 16.
    Khan I (2002) Antisense inhibition of cyclooxygenase-2 causes a selective suppression of the Na+–H+ exchanger isoform 3 in rat kidney in experimental colitis. Nephron 91(1):120–128. doi: 10.1159/000057613 PubMedCrossRefGoogle Scholar
  17. 17.
    Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78(3):206–209. doi: 10.1111/1523-1747.ep12506462 PubMedCrossRefGoogle Scholar
  18. 18.
    Khan I, Al-Awadi FM, Thomas N (2001) In vivo inhibition of cyclooxygenase-2 by a selective phosphorothioated oligonucleotide. Antisense Nucleic Acid Drug Dev 11(4):199–207. doi: 10.1089/108729001317022205 PubMedCrossRefGoogle Scholar
  19. 19.
    Wang K, Wan YJ (2008) Nuclear receptors and inflammatory diseases. Exp Biol Med (Maywood) 233(5):496–506. doi: 10.3181/0708-MR-231 (Review)CrossRefGoogle Scholar
  20. 20.
    Hogaboam CM, Vallance BA, Kumar A, Addison CL, Graham FL, Gauldie J, Collins SM (1997) Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest 100(11):2766–2776. doi: 10.1172/JCI119823 PubMedCrossRefGoogle Scholar
  21. 21.
    Arranz A, Juarranz Y, Leceta J, Gomariz RP, Martínez C (2008) VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides 29(6):948–956. doi: 10.1016/j.peptides.2008.01.019 PubMedCrossRefGoogle Scholar
  22. 22.
    Arranz A, Abad C, Juarranz Y, Torroba M, Rosignoli F, Leceta J, Gomariz RP, Martínez C (2006) Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Ann N Y Acad Sci 1070:129–134. doi: 10.1196/annals.1317.001 PubMedCrossRefGoogle Scholar
  23. 23.
    Araki A, Kanai T, Ishikura T, Makita S, Uraushihara K, Iiyama R, Totsuka T, Takeda K, Akira S, Watanabe M (2005) MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol 40:16–23. doi: 10.1007/s00535-004-1492-9 PubMedCrossRefGoogle Scholar

For further reading

  1. 24.
    Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y (2006) Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4(12):1502–1506PubMedCrossRefGoogle Scholar
  2. 25.
    Bremner P, Heinrich M (2002) Natural products as targeted modulators of the nuclear factor-kappaB pathway. J Pharm Pharmacol 54(4):453–472 (Review)PubMedCrossRefGoogle Scholar
  3. 26.
    Jian YT, Wang JD, Mai GF, Zhang YL, Lai ZS (2004) Modulation of intestinal mucosal inflammatory factors by curcumin in rats with colitis. Di Yi Jun Yi Da Xue Xue Bao 24(12):1353–1358 (Chinese)PubMedGoogle Scholar
  4. 27.
    Fukata M, Abreu MT (2007) TLR4 signalling in the intestine in health and disease. Biochem Soc Trans 35(Pt 6):1473–1478 (Review)PubMedCrossRefGoogle Scholar
  5. 28.
    Zhang R, Li Y, Beck PL, McCafferty DM (2007) Toll-like receptor 4 regulates colitis-associated adenocarcinoma development in interleukin-10-deficient (IL-10(-/-) mice. Biochem Soc Trans 35(Pt 5):1375–1376 (Review)PubMedGoogle Scholar
  6. 29.
    Cario E (2008) Therapeutic impact of toll-like receptors on inflammatory bowel diseases: a multiple-edged sword. Inflamm Bowel Dis 14(3):411–421 (Review)PubMedCrossRefGoogle Scholar
  7. 30.
    Santin I, Castellanos-Rubio A, Hualde I, Castaño L, Vitoria JC, Bilbao JR (2007) Toll-like receptor 4 (TLR4) gene polymorphisms in celiac disease. Tissue Antigens 70(6):495–498PubMedCrossRefGoogle Scholar
  8. 31.
    Browning BL, Huebner C, Petermann I, Gearry RB, Barclay ML, Shelling AN, Ferguson LR (2007) Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol 102(11):2504–2512PubMedCrossRefGoogle Scholar
  9. 32.
    Kullberg BJ, Ferwerda G, de Jong DJ, Drenth JP, Joosten LA, Van der Meer JW, Netea MG (2008) Crohn’s disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Immunology 123(4):600–605PubMedCrossRefGoogle Scholar
  10. 33.
    Heimesaat MM, Fischer A, Jahn HK, Niebergall J, Freudenberg M, Blaut M, Liesenfeld O, Schumann RR, Göbel UB, Bereswill S (2007) Exacerbation of murine ileitis by toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli. Gut 56(7):941–948PubMedCrossRefGoogle Scholar
  11. 34.
    Ishihara S, Rumi MA, Ortega-Cava CF, Kazumori H, Kadowaki Y, Ishimura N, Kinoshita Y (2006) Therapeutic targeting of toll-like receptors in gastrointestinal inflammation. Curr Pharm Des 12(32):4215–4228 (Review)PubMedCrossRefGoogle Scholar
  12. 35.
    Barton GM, Medzhitov R (2003) Toll-like receptor signaling pathways. Science 300:1524–1525PubMedCrossRefGoogle Scholar
  13. 36.
    Baumgart DC, Dignass AU (2004) Current biological therapies for inflammatory bowel disease. Curr Pharm Des 10:4127–4147PubMedCrossRefGoogle Scholar
  14. 37.
    Beutler B (2002) TLR-4 as the mammalian endotoxin sensor. Curr Top Microbiol Immunol 270:109–120PubMedGoogle Scholar
  15. 38.
    Furrie E, Macfarlane S, Thomson G, Macfarlane GT (2005) Toll-like receptors-2, -3, and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 115:565–574PubMedCrossRefGoogle Scholar
  16. 39.
    Guslandi M (2005) Antibiotics for inflammatory bowel disease: do they work? Eur J Gastroenterol Hepatol 17:145–147PubMedCrossRefGoogle Scholar
  17. 40.
    Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK (2003) Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 139(2):209–218PubMedCrossRefGoogle Scholar
  18. 41.
    Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995PubMedCrossRefGoogle Scholar
  19. 42.
    Kirschning CJ, Schumann RR (2002) TLR-2: cellular sensor for microbial and endogenous molecular patterns. Curr Top Microbiol Immunol 270:121–144PubMedGoogle Scholar
  20. 43.
    Kuhl AA, Loddenkemper C, Westermann J, Hoffmann JC (2002) Role of gamma delta T cells in inflammatory bowel disease. Pathobiology 70:150–155PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  1. 1.Departments of Biochemistry, Pharmacology, Faculty of MedicineKuwait UniversitySafatKuwait

Personalised recommendations